Core Insights - The company reported a significant increase in net profit, reaching 150 million yuan, a year-on-year growth of 41.6% [1] - EBITDA reached 270 million yuan, reflecting a year-on-year increase of 37.3%, indicating strong operational efficiency and cost control [1] - The impressive performance is attributed to the dual strategies of cost reduction and business focus, enhancing profitability and operational resilience [1] Financial Performance - Revenue for the first half of 2025 was 1.49 billion yuan, representing a growth of 9.5% [2] - Growth drivers included the "same city expansion + new city development" strategy, with new branches entering profitability and contributing stable revenue [2] - The number of repeat patients increased by 14.8% due to refined operational tools and AI health assistants, further boosting overall performance [2] Profitability and Efficiency - The company's gross profit margin improved to 30.6%, benefiting from a decrease in expense and cost ratios due to scale growth [2] - High-margin self-priced product revenue surged by 209.1%, alongside significant growth in self-funded projects like traditional Chinese medicine therapies [2] - Administrative and sales expense ratios decreased, contributing to the 37.3% growth in EBITDA, showcasing enhanced profitability [2] Future Outlook - The company is positioned to continue delivering high profit growth and quality optimization, supported by national policies promoting the traditional Chinese medicine industry [2]
固生堂：EBITDA大增37.3% 成长潜力持续释放